Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Radiopharm Theranostics received a positive recommendation from the Data Safety and Monitoring Committee to advance its Phase 1 clinical trial of 177Lu-RAD202 to a higher dose level of 180mCi in patients with HER2-positive advanced solid tumors. This advancement follows encouraging safety and biodistribution results in earlier cohorts, marking prog…